Amicus Therapeutics Presents Additional Positive Preliminary Phase 1/2 Data at WORLDSymposium 2017; Biomarkers of Muscle Damage (AST, ALT and CK) Demonstrate Improving Trends in Majority of Patients
Charles Gross